Gideon Kwok
Rancho Cucamonga, CANPI 1700023520
Payments from drug & device makers
$1,334,117in general payments, 2019–2025
Across 676 payments — averaging $1973.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$598K
- Galderma Laboratories, L.p.$538K
- Merz North America, Inc.$198K
- Revance Therapeutics, Inc.$333
- Solta Medical, A Division Of Bausch Health US, LLC$25
- Philips North America LLC$20
- plus $17 from 1 others
What the payments were for
- Consulting fees$174,10613%
- Speaking & faculty fees$1,105,14583%
- Travel & lodging$34,1703%
- Food & beverage$20,4582%
- Education$2380%
General payments by program year
19
20
21
22
23
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $597,795 |
| Galderma Laboratories, L.p. | 442 | $537,933 |
| Merz North America, Inc. | 188 | $197,993 |
| Revance Therapeutics, Inc. | 5 | $333 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $25 |
| Philips North America LLC | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$80,708
- ASCLERA$695
- BOTOX$210
- BOTOX COSMETIC$119
- DAXXIFY$100
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.